Boosting Antioxidant Defense: The Effect of Astaxantin on Superoxidase Dismutase and Malondialdehyde Reduction in Patients with Head and Neck Cancer Receiving Cisplatin Chemotherapy
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Astaxanthin supplementation significantly reduced malondialdehyde (MDA) levels in head and neck cancer (HNC) patients undergoing cisplatin chemotherapy. While superoxide dismutase (SOD) levels did not show a significant increase, MDA reduction highlights astaxanthin's antioxidant benefits.
Area Of Science
- Biochemistry
- Oncology
- Nutritional Science
Background
- Cisplatin chemotherapy for head and neck cancer (HNC) can increase oxidative stress, leading to decreased superoxide dismutase (SOD) and increased malondialdehyde (MDA).
- Astaxanthin, a potent antioxidant, is investigated for its potential to counteract these reactive oxygen species (ROS)-induced changes.
Purpose Of The Study
- To evaluate the efficacy of astaxanthin in modulating SOD and MDA levels in HNC patients undergoing cisplatin treatment.
- To compare the effects of astaxanthin with a combination of vitamin C and vitamin E.
Main Methods
- A double-blind, randomized controlled trial with a pre-post test design involving 42 HNC patients.
- The treatment group received astaxanthin (4 mg BID), while the control group received vitamin C (500 mg) and vitamin E (250 mg IU).
- Statistical analysis using the Mann Whitney test to compare changes in SOD and MDA levels between groups.
Main Results
- A significant reduction in MDA levels was observed in the astaxanthin group (p=0.000).
- No significant difference was found in the delta reduction of SOD levels between the astaxanthin and vitamin C & E groups (p=0.443).
- The study included patients with various HNC types, stages, and treatment regimens, with a mean age of 48.2 years.
Conclusions
- Astaxanthin supplementation for 21 days demonstrated a significant ability to decrease MDA levels in HNC patients receiving cisplatin chemotherapy.
- While not significantly impacting SOD, the observed reduction in MDA suggests astaxanthin's potential as an adjunct therapy to mitigate cisplatin-induced oxidative stress.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...